Ovarian Cancer Trial, Recruiting NCT06760507 Sponsor: Emory University Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT06760507
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

This trial has several different parts, and each part has its own eligibility requirements:

Part 1 – Advisory Committee:

  • People representing one of three groups: state cancer control leaders, public health clinic staff or directors from the Southwest district, or women aged 25 and older who receive care in the Southwest district

Part 1 – Discussion Forum:

  • Women aged 25 and older
  • People who speak English
  • People who completed a family health history screening in the first 3 months of the project at one of 14 public health clinics in the Southwest district

Part 1 – Stakeholder Interviews:

  • Medical directors, nurses, and clinic staff working at the 14 clinic sites in the Southwest district

Part 2 – Main Study:

  • Women aged 25 and older
  • People who are able to read English
  • People who have previously been seen at the Women's Health Section through one of the participating public health clinics in the Southwest district

Part 3 – Follow-Up Interviews:

  • People who took part in Part 2, whether or not they completed the recommended genetic services

Part 3 – Workshop Discussion:

  • Medical directors, administrators, nurses, and clinic staff from the six participating clinic sites

Who may not be able to join:

  • People who do not meet the age requirement of 25 or older (for the relevant parts)
  • People who are not women (for the parts that require female participants)
  • People who cannot read or speak English (for the relevant parts)
  • People who have not received care at a participating Southwest district public health clinic (for the relevant parts)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yue Guan, Emory University Hospital/Winship Cancer Institute

Phone: 404-712-1671

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 February 2025
Est. completion
30 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Uptake of family history screening; Screen result interpretation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov